Longest survival follow-up ever reported for immunotherapy treatment in this setting
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
Comprehensive clinical development programs being initiated for each investigational candidate
The company has received five final approvals
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
Almost 300 million people globally have chronic hepatitis B
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
Subscribe To Our Newsletter & Stay Updated
